Breast Cancer PSMA PET
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18 lat lub więcej
- •Nowotwór piersi z przerzutami w organizmie (potwierdzona diagnoza)
- •Wyniki badania PET/CT pokazujące aktywne ogniska przerzutów
✗ Disqualifies
- •Aktywny nowotwór lub inna choroba nowotworowa
- •Niemożność tolerowania badania PET/CT
- •Ciąża lub karmienie piersią
- •Schorzenia mogące zagrażać bezpieczeństwu podczas badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- March 27, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University of Iowa Healthcare
Iowa City, United States
Trial contact
Ahmad Shariftabrizi, M.D.
Elina Shrestha
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.